A recent review reported that low expression of SETDB2 was associated with shorter disease-free survival time in renal cell tumors, while in gastric cancer, SETDB2 overexpression predicted poor prognoses and was associated with tumor progression (Torrano et al., 2019). The gene discussed is SETDB2; the disease is neoplasm.